Genomic and computational-aided integrative drug repositioning strategy for EGFR and ROS1 mutated NSCLC
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112682 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Varsha Tripathi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Dr. Ram Manohar Lohia Avadh University Ayodhya, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Drug Repositioning, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, ErbB Receptors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 88 Literaturangaben.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) has been marked as the major cause of death in lung cancer patients. Due to tumor heterogeneity, mutation burden, and emerging resistance against the available therapies in NSCLC, it has been posing potential challenges in the therapy development. Hence, identification of cancer-driving mutations and their effective inhibition have been advocated as a potential approach in NSCLC treatment. Thereof, this study aims to employ the genomic and computational-aided integrative drug repositioning strategy to identify the potential mutations in the selected molecular targets and repurpose FDA-approved drugs against them. Accordingly, molecular targets and their mutations, i.e., EGFR (V843L, L858R, L861Q, and P1019L) and ROS1 (G1969E, F2046Y, Y2092C, and V2144I), were identified based on TCGA dataset analysis. Following, virtual screening and redocking analysis, Elbasvir, Ledipasvir, and Lomitapide drugs for EGFR mutants (>-10.8 kcal/mol) while Indinavir, Ledipasvir, Lomitapide, Monteleukast, and Isavuconazonium for ROS1 mutants (>-8.8 kcal/mol) were found as putative inhibitors. Furthermore, classical molecular dynamics simulation and endpoint binding energy calculation support the considerable stability of the selected docked complexes aided by substantial hydrogen bonding and hydrophobic interactions in comparison to the respective control complexes. Conclusively, the repositioned FDA-approved drugs might be beneficial alone or in synergy to overcome acquired resistance to EGFR and ROS1-positive lung cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Dr. Ram Manohar Lohia Avadh University Ayodhya, Uttar Pradesh, India.
- Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India; Computational Chemistry & Drug Discovery Division, Qu…
- Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic. Electronic address: shiv.bharadwaj@ibt.cas.cz.
- School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju, Republic of Korea. Electronic address: nkirtipal5@gist.ac.kr.
- Department of Biochemistry, Dr. Ram Manohar Lohia Avadh University Ayodhya, Uttar Pradesh, India. Electronic address: Vandanaranjan@rmlau.ac.in.
Zitieren
APA
Tripathi, V., Khare, A., Shukla, D., Bharadwaj, S., Kirtipal, N., & Ranjan, V. (2024). Genomic and computational-aided integrative drug repositioning strategy for EGFR and ROS1 mutated NSCLC. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112682
Vancouver
Tripathi V, Khare A, Shukla D, Bharadwaj S, Kirtipal N, Ranjan V. Genomic and computational-aided integrative drug repositioning strategy for EGFR and ROS1 mutated NSCLC. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112682
BibTeX
@article{Tripathi2024,
author = {Tripathi, Varsha and Khare, Aishwarya and Shukla, Divyanshi and Bharadwaj, Shiv and Kirtipal, Nikhil and Ranjan, Vandana},
title = {Genomic and computational-aided integrative drug repositioning strategy for EGFR and ROS1 mutated NSCLC},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112682}
}
EUVIMED